SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

NEONC TECHNOLOGIES HOLDINGS, INC.
Date: April 7, 2026 · CIK: 0001979414 · Accession: 0000000000-26-003499

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-294845

Date
April 7, 2026
Author
Division of
Form
UPLOAD
Company
NEONC TECHNOLOGIES HOLDINGS, INC.

Letter

Re: NeOnc Technologies Holdings, Inc. Registration Statement on Form S-3 Filed April 02, 2026 File No. 333-294845 Dear Amir Heshmatpour:

April 7, 2026

Amir Heshmatpour Chief Executive Officer NeOnc Technologies Holdings, Inc. 23975 Park Sorrento, Suite 205 Calabasas, CA 91302

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Doris Stacey Gama at 202-551-3188 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Tom Poletti, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                           April 7, 2026

Amir Heshmatpour
Chief Executive Officer
NeOnc Technologies Holdings, Inc.
23975 Park Sorrento, Suite 205
Calabasas, CA 91302

       Re: NeOnc Technologies Holdings, Inc.
           Registration Statement on Form S-3
           Filed April 02, 2026
           File No. 333-294845
Dear Amir Heshmatpour:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Doris Stacey Gama at 202-551-3188 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Tom Poletti, Esq.
</TEXT>
</DOCUMENT>